今日药学

2015, v.25(05) 340-342

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

长效干扰素序贯恩替卡韦与单用恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的比较
A Comparison of Sequential Treatment by Peg-Interferon and Entecavir with Entecavir Mono-Therapy to Chronic Hepatitis B with Positive HBeAg

唐奇远;何清;唐情容;唐蔚;赖长祥;
TANG Qiyuan;HE Qing;TANG Qingrong;TANG Wei;LAI Changxiang;The Third People's Hospital of Shenzhen;

摘要(Abstract):

目的观察和比较长效干扰素序贯恩替卡韦与单用恩替卡韦治疗HBe Ag阳性慢性乙型肝炎疗效。方法收集60例HBe Ag阳性慢性乙型肝炎患者并分为2组(各30例),其中序贯治疗组予以长效干扰素治疗24周,再序贯恩替卡韦治疗24周,恩替卡韦组单用恩替卡韦治疗48周,比较48周时2组患者疗效的差别。结果 2组患者的HBV DNA阴转率差异无统计学意义(χ2=1.92,P=0.166);ALT复常率差异无统计学意义(χ2=0.7407,P=0.389);序贯治疗组患者的HBe Ag转换率高于恩替卡韦组(χ2=5.079 4,P=<0.05)。结论与单用恩替卡韦相比,序贯治疗在免疫控制方面能取得更为理想的疗效。
OBJECTIVE To compare the curative effect of sequential treatment by peg-interferon and entecavir with entecavir mono-therapy to chronic hepatitis B with positive HBe Ag. METHODS A total of 60 patients of chronic hepatitis B with positive HBe Ag were collected,and then were equally divided into 2 groups. Patients in one group were treated by peg-interferon for 24 weeks,and followed up by entecavir for 24 weeks,while patients in another group were treated by entecavir for 48 weeks. Then the curative effect of 2 groups was compared. RESULTS There was no significant difference in HBV DNA seroconversion rates( χ2= 1. 92,P = 0.166) and ALT recovery rate( χ2= 0. 7407,P = 0. 389) between 2 groups. The HBe Ag seroconversion rate of sequential group was higher than that of the entecavir group( χ2= 5. 0794,P = < 0. 05). CONCLUSION Compared with the treatment of entecavir monotherapy,sequential treatment can get better curative effect in immunity control.

关键词(KeyWords): 肝炎;乙型;慢性;干扰素;恩替卡韦
hepatitis B;chronic;interferon;entecavir

Abstract:

Keywords:

基金项目(Foundation): 广东省药学会肝炎用药研究基金(2011G16);; 深圳市科技计划项目(201103127)

作者(Authors): 唐奇远;何清;唐情容;唐蔚;赖长祥;
TANG Qiyuan;HE Qing;TANG Qingrong;TANG Wei;LAI Changxiang;The Third People's Hospital of Shenzhen;

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享